Clinical Trial Update: Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating eltrombopag targeting the Bcl-xL pathway in idiopathic thrombocytopenic purpura (immune thrombocytopenia) completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura
• Immune Thrombocytopenia

Drugs mentioned

• Eltrombopag (eltrombopag)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Immune Thrombocytopenia | Phase 2 | Status: COMPLETED | Results posted: 2019-03-18